Use app for best experience!
Available for Android Device.

Glenmark Life Sciences Limited IPO Detail

Glenmark Life Sciences Limited IPO Detail

Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

Competitive strengths

  • Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
  • Export products in Europe, Latin America, North America, Japan, and the rest of the world.
  • Strong relationship with leading global generic companies.
  • Proven track record of strong financial performance.
  • High-quality product manufacturing with R&D infrastructure.

Company Promoters

Glenmark Pharmaceuticals Limited is the promoter of the company.

IPO Details

IPO Opening DateJul 27, 2021
IPO Closing DateJul 29, 2021
Issue TypeBook Built Issue IPO
Face Value₹2 per equity share
IPO Price ₹695 - 720 per equity share
Market Lot20 Shares
Min Order Quantity20 Shares
Listing AtBSE, NSE
Issue Size₹1,513.60 Cr
Fresh Issue[.] Eq Shares of ₹2 (aggregating up to ₹1,060.00 Cr)
Offer for Sale6,300,000 Eq Shares of ₹2 (aggregating up to ₹453.60 Cr)
Retail Portion 35%

IPO Subscription (Bidding Detail)

Day 1 0.00x 0.86x 5.17x - 2.78x
Day 2 1.38x 3.39x 9.28x - 5.78x
Day 3 36.97x 122.54x 14.63x - 44.17x

IPO Tentative Timetable

The Glenmark Life Sciences Limited IPO open date is Jul 27, 2021, and the close date is Jul 29, 2021. The issue may list on Aug 06, 2021.

IPO Open DateJul 27, 2021
IPO Close DateJul 29, 2021
Basis of Allotment DateAug 03, 2021
Initiation of RefundsAug 04, 2021
Credit of Shares to Demat AccountAug 05, 2021
IPO Listing DateAug 06, 2021

IPO Lot Size

The Glenmark Life Sciences Limited IPO market lot size is 20 shares. A retail-individual investor can apply for up to 13 lots (260 shares or ₹187200).

ApplicationLotsSharesAmount (Cut-off)

Company Financials:

For the year/period ended (₹ in Crs)

Financial Year Total Assets Total Revenue Profit After Tax
31-Dec-20 1,956.57 1,418.47 246.89
31-Mar-20 1,725.60 1,549.3 313.09
31-Mar-19 1,475.39 886.86 195.59

Objects of the Issue:

  • To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
  • To finance capital expenditure requirements.
  • To meet general corporate purposes.